TITLE

Drug tested for use in geographic atrophy

PUB. DATE
May 2006
SOURCE
Ophthalmology Times;5/1/2006, Vol. 31 Issue 9, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the phase II clinical trial by the National Eye Institute (NEI) of the topical eye drop OT-551 from Othera Pharmaceuticals Inc., in patients with geographic atrophy (GA). The potential of the drug in slowing the enlargement of the atrophic area in the macula will be investigated by the NEI. The percent change in area of GA in each eye is the primary efficacy measure. Secondary measures of the phase II study are discussed.
ACCESSION #
20787257

 

Related Articles

  • Keeping an eye on the AMD market. Belden, Heidi // Drug Topics;12/10/2007, Vol. 151 Issue 23, p20 

    The article discusses developments in drug products for the management of age-related macular degeneration (AMD) in the U.S. Othera Pharmaceuticals is analyzing the use of OT-551 for the treatment of geographic atrophy, an advanced form of dry AMD. It is also conducting another phase II study of...

  • Athenagen begins testing ATG003.  // Ophthalmology Times;10/15/2006, Vol. 31 Issue 20, p8 

    The article reports that Athenagen Inc. has started phase I clinical testing of ATG003, a topical eye drop therapy for age-related macular degeneration (AMD) in San Francisco, California. The company announced that the randomized, placebo-controlled, ascending-dose clinical trial is designed to...

  • Outcomes in Cochrane Systematic Reviews Addressing Four Common Eye Conditions: An Evaluation of Completeness and Comparability. Saldanha, Ian J.; Dickersin, Kay; Wang, Xue; Li, Tianjing // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Introduction: Choice of outcomes is critical for clinical trialists and systematic reviewers. It is currently unclear how systematic reviewers choose and pre-specify outcomes for systematic reviews. Our objective was to assess the completeness of pre-specification and comparability of outcomes...

  • Othera sees positive interim results for OT-551.  // Ophthalmology Times;5/1/2009, Vol. 34 Issue 9, p12 

    The article reports on the result of the phase II trial of OT-551 conducted by Othera Pharmaceuticals Inc. in Exton, Pennsylvania. It notes that OT-551 is intended to cure geographic atrophy (GA) and to treat for dry age-related macular degeneration (AMD). Result of the study suggests that an...

  • AMD Drugs' Progress Reported At ASRS Meeting.  // Review of Ophthalmology;Oct2006, Vol. 13 Issue 10, p11 

    The article presents information on the September meeting of the combined American and European Societies of Retina Specialists that features updating trials of macular degeneration drugs. A two-year study results were presented by the MARINA study that tested 716 patients. Around 92 percent of...

  • Sight preserved in AMD patients receiving steroid derivative. Charters, Lynda // Ophthalmology Times;11/1/2003, Vol. 28 Issue 31, p59 

    Reports that findings from a phase II/III study conducted by the Anecortave Acetate Clinical Study Group indicate that anecortave acetate can have a positive impact on the treatment of patients with age-related macular degeneration (AMD). Long-term benefits that anecortave acetate can provide...

  • Vascular targeting to start phase I/II trial for patients with wet AMD.  // Ophthalmology Times;8/15/2003, Vol. 28 Issue 16, p30 

    Focuses on the start of the phase I/II clinical trial of the vascular targeting agent Combretastatin A4 Prodrug for wet age-related macular degeneration (AMD). Treatment of cancer in patients with wet AMD.

  • Ophthalmology: Interpreting the Avastin-Lucentis study for persons with macular degeneration.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that the American Health Assistance Foundation is looking forward to discoveries from Comparison of AMD Treatments Trials (CATT) on age-related macular degeneration (AMD).

  • A New Approach to AMD Treatment.  // Review of Ophthalmology;Aug2003, Vol. 10 Issue 8, p15 

    Reports on the release of the phase I/II clinical trial at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine to determine the safety and efficacy of the vascular-targeting agent Combretastin A4-phosphate Prodrug for the treatment of wet age-related macular degeneration...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics